Warning: The NCBI web site requires JavaScript to function. more...
Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.
King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG.
Breast Cancer Res. 2004;6(5):R478-87. Epub 2004 Jun 28.
Related citations
Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis.
Davies SR, Dent C, Watkins G, King JA, Mokbel K, Jiang WG.
Oncol Rep. 2008 Feb;19(2):555-61.
Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers.
Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K, Mansel RE.
Clin Cancer Res. 2003 Dec 15;9(17):6432-40.
Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Motyl T.
Med Sci Monit. 2006 Jul;12(7):BR245-56. Epub 2006 Jun 28.
Is N-cadherin expression important in ductal carcinoma?
King JA, Shevde LA, Ofori-Acquah S, Watkins G, Jiang WG.
South Med J. 2008 May;101(5):470-5.
Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G.
J Clin Pathol. 2006 Apr;59(4):403-9. Epub 2006 Feb 16.
Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Jiang WG, Douglas-Jones AG, Mansel RE.
Prostaglandins Leukot Essent Fatty Acids. 2006 Feb;74(2):125-34. Epub 2005 Dec 20.
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M, Reed MJ, Al Sarakbi W, Jiang WG, Mokbel K.
Breast Cancer Res Treat. 2006 Sep;99(2):155-62. Epub 2006 Mar 16.
Expression of Com-1/P8 in human breast cancer and its relevance to clinical outcome and ER status.
Jiang WG, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE, Fodstad O.
Int J Cancer. 2005 Dec 10;117(5):730-7.
Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases.
Ihnen M, Köhler N, Kersten JF, Milde-Langosch K, Beck K, Höller S, Müller V, Witzel I, Jänicke F, Kilic E.
Dis Markers. 2010;28(2):71-8.
Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.
Sasi W, Jiang WG, Sharma A, Mokbel K.
BMC Cancer. 2010 Apr 30;10:178.
The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W, Mokbel R, Salhab M, Jiang WG, Reed MJ, Mokbel K.
Anticancer Res. 2006 Nov-Dec;26(6C):4985-90.
The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.
Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG.
Int J Mol Med. 2007 Oct;20(4):605-11.
Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa BW, Jänicke F, Milde-Langosch K.
Breast Cancer Res Treat. 2008 Dec;112(3):419-27. Epub 2008 Jan 3.
[Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
Kilic E, Milde-Langosch K, Müller V, Wirtz R, Ihnen M.
Pathologe. 2008 Nov;29 Suppl 2:347-52. German.
Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients.
Parr C, Gan CH, Watkins G, Jiang WG.
Angiogenesis. 2006;9(2):73-81. Epub 2006 Jun 7.
LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
Anticancer Res. 2004 Jul-Aug;24(4):2391-400.
ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
Jezierska A, Matysiak W, Motyl T.
Med Sci Monit. 2006 Aug;12(8):BR263-73. Epub 2006 Jul 12.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer.
Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton AR Jr.
Cancer Res. 2003 Oct 15;63(20):6772-83. Erratum in: Cancer Res. 2003 Dec 1;63(23):8562.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on